{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:48:35Z","timestamp":1783360115882,"version":"3.54.6"},"update-to":[{"DOI":"10.1002\/14651858.cd006264","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000}}],"reference-count":44,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006264.pub2","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T20:11:33Z","timestamp":1202242293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Corticosteroids for the long-term treatment in multiple sclerosis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Alfonso","family":"Ciccone","sequence":"first","affiliation":[{"name":"Azienda Ospedale Niguarda Ca' Granda; Department of Neurology; Piazza Ospedale Maggiore 3 Milano Italy 20162"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Beretta","sequence":"additional","affiliation":[{"name":"A.O. Ospedale Civile di Vimercate e Desio; Neurology; Via C. Batisti, 23 Vimercate Italy 20059"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Brusaferri","sequence":"additional","affiliation":[{"name":"Ospedale Maggiore di Crema; U.O. Neurology; Largo Ugo Dossena, 2 Crema Cremona Italy 26013"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Galea","sequence":"additional","affiliation":[{"name":"Wessex Neurosciences Centre; Department of Neurology; Mailpoint 101 Southampton University Hospitals Trust, Tremona Road Southampton Hampshire UK SO16 6YD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Protti","sequence":"additional","affiliation":[{"name":"Azienda Ospedale Niguarda Ca' Granda; Department of Neurology; Piazza Ospedale Maggiore 3 Milano Italy 20162"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Azienda Ospedale Niguarda Ca' Granda; Department of Neurology; Piazza Ospedale Maggiore 3 Milano Italy 20162"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"key":"10.1002\/14651858.CD006264.pub2-BIB0001|cit1","unstructured":"Ciccone A Beretta S Pellegrini G and the BPSM Group Periodic intravenous methylprednisolone megadoses to prevent relapses in multiple sclerosis Protocol approved by local Ethics Committee (Ospedale \"Valduce\", Como, Italy) 1995"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(61)91308-3","article-title":"Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin","volume":"1","author":"Miller","year":"1961","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0004|cit3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2005.03.006","article-title":"Steroids and brain atrophy in multiple sclerosis","volume":"233","author":"Zivadinov","year":"2005","journal-title":"Journal of Neurological Sciences"},{"issue":"7","key":"10.1002\/14651858.CD006264.pub2-BIB0003|cit4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.57.7.1239","article-title":"Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS","volume":"57","author":"Zivadinov","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-1331.2005.00988.x","article-title":"Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis","volume":"12","author":"Zorzon","year":"2005","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0006|cit6","unstructured":"Beretta S Battistel A Checcarelli N Garavaglia P Guidotti M Manfredi L Efficacy of repeated methylprednisolone megadoses in modifying the prognosis of relapsing remitting multiple sclerosis Journal of Neurology 1997 S64"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0007|cit7","unstructured":"Beretta S Checcarelli N Manfredi L Adobbati L Garavaglia P Guidotti M XXXVII Congresso Nazionale della Societ\u00e0 dei Neurologi Neurochirurghi e Neuroradiologi Ospedalieri (S.N.O.) Como 1997 37 8"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0008|cit8","unstructured":"Beretta S Ciccone A Manfredi L Garavaglia P Adobbati L Checcarelli N Prophylaxis of multiple sclerosis recurrences using repeated high dose pulses of i.v. steroids Journal of Neurology 1996 81"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0009|cit9","first-page":"389","article-title":"Efficacy of methylprednisolone megadoses in preventing exacerbations of relapsing remitting multiple sclerosis","volume":"43","author":"Beretta","year":"1997","journal-title":"Rivista di Neurobiologia"},{"issue":"5","key":"10.1002\/14651858.CD006264.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1191\/1352458504ms1079sr","article-title":"Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis","volume":"10","author":"Seze","year":"2004","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD006264.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/WNL.51.1.239","article-title":"A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis","volume":"51","author":"Goodkin","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006264.pub2-BIB0012|cit12","first-page":"501","article-title":"Cerebral atrophy in multiple sclerosis patients treated periodically with boluses of methylprednisolone","volume":"37","author":"Pato-Pato","year":"2003","journal-title":"Revista de Neurologia"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0013|cit13","unstructured":"Piazza G Italian multicentre randomised controlled prospective study with parallel groups to compare the efficacy of the treatment with Interferon beta 1b to interferon beta 1b plus methylprednisolone in patients with secondary progressive multiple sclerosis. Protocol approved by Local Ethics Committees"},{"issue":"7","key":"10.1002\/14651858.CD006264.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/archneur.61.7.1148","article-title":"Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial","volume":"61","author":"Pirko","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2377-6-19","article-title":"Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations","volume":"6","author":"Then Bergh","year":"2006","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/archneur.1965.00460290092010","article-title":"Use of an oral corticosteroid in the treatment of multiple sclerosis. A Double -Blind Study","volume":"12","author":"Tourtellotte","year":"1965","journal-title":"Archives of Neurology"},{"issue":"11","key":"10.1002\/14651858.CD006264.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.56.11.1219","article-title":"Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose","volume":"56","author":"Alam","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006264.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/BF00612124","article-title":"Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis","volume":"36","author":"Barkhof","year":"1994","journal-title":"Neuroradiology"},{"issue":"24","key":"10.1002\/14651858.CD006264.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group","volume":"329","author":"Beck","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archopht.1995.01100020014004","article-title":"The Optic Neuritis Treatment Trial: three-year follow-up results","volume":"113","author":"Beck","year":"1995","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006264.pub2-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001331","article-title":"Corticosteroids or ACTH for acute exacerbations in multiple sclerosis","author":"Filippini","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006264.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archneur.62.10.1519","article-title":"Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations","volume":"62","author":"Frohman","year":"2005","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006264.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0404.1997.tb00099.x","article-title":"The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients","volume":"95","author":"Gasperini","year":"1997","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(01)00330-7","article-title":"Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders","volume":"117","author":"Gold","year":"2001","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"10.1002\/14651858.CD006264.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1212\/WNL.51.6.1689","article-title":"A serial study of new MS lesions and the white matter from which they arise","volume":"51","author":"Goodkin","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0030|cit30","unstructured":"Higgins JPT Green S Chapter 6: Searching for studies. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] The Cochrane Library Issue 3 2005"},{"issue":"11","key":"10.1002\/14651858.CD006264.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006264.pub2-BIB0032|cit32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002127.pub2","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006264.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/oxfordjournals.bmb.a071393","article-title":"Diagnosis and classification of multiple sclerosis","volume":"33","author":"McDonald","year":"1977","journal-title":"British Medical Bullettin"},{"issue":"1","key":"10.1002\/14651858.CD006264.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006264.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006264.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006264.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2004.04.019","article-title":"Corticosteroids treatment","volume":"223","author":"Pozzilli","year":"2004","journal-title":"Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006264.pub2-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0039|cit39","first-page":"8","article-title":"Current approved options for treating patients with multiple sclerosis","volume":"63 Suppl 6","author":"Rizvi","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0040|cit40","first-page":"47","article-title":"Other therapy options and future strategies for treating patients with multiple sclerosis","volume":"63 Suppl 6","author":"Rizvi","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD006264.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ana.410330511","article-title":"Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions","volume":"33","author":"Smith","year":"1993","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD006264.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1212\/WNL.45.10.1808","article-title":"Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis","volume":"45","author":"Stone","year":"1995","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006264.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-1331.2005.00988.x","article-title":"Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis","volume":"12","author":"Zorzon","year":"2005","journal-title":"European Journal of Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006264.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:46:37Z","timestamp":1765557997000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006264.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006264.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}